P53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy

European Journal of Cancer

Volumn 48, Issue 10, 2012, Pages 1570-1580

  Attias Geva, Zohar ^a   Bentov, Itay ^a   Kidron, Dvora ^b   Amichay, Keren ^b   Sarfstein, Rive ^a   Fishman, Ami ^b   Bruchim, Ilan ^b   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Endometrial cancer; IGF I receptor; Insulin like growth factor I (IGF I); p53; Transcription regulation

Indexed keywords

ANTINEOPLASTIC AGENT; CITUXUMUMAB; MITHRAMYCIN A; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN P53; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN LIKE GROWTH FACTOR I RECEPTOR GENE; METASTASIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTOR, IGF TYPE 1; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS; ZINC FINGERS;

EID: 84862026329     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.014     Document Type: Article

References (53)

1. S. Chang, L.C. Mâsse, and R.P. Moser State ranks of incident cancer burden due to overweight and obesity in the United States, 2003 Obesity (Silver Spring) 16 2008 1636 1650
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
3. C.A. Hamilton, M.K. Cheung, and K. Osann Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
4. B.A. Goff, D. Kato, and R.A. Schmidt Uterine papillary serous carcinoma: patterns of metastatic spread Gynecol Oncol 54 1994 264 268
5. H. Tashiro, C. Isacson, and R. Levine p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis Am J Pathol 150 1997 177 185
6. L. Jia, Y. Liu, and X. Yi Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma Clin Cancer Res 14 2008 2263 2269
7. K. Ito, K. Watanabe, and S. Nasim Prognostic significance of p53 overexpression in endometrial cancer Cancer Res 54 1994 4667 4670
8. B. Powell, R. Soong, and F. Grieu p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma Int J Oncol 14 1999 175 179
9. D. Bancher-Todesca, G. Gitsch, and K. Williams p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma Gynecol Oncol 71 1998 59 63
10. S. Kovalev, N. Marchenko, and B. Gugliotta Loss of p53 function in uterine papillary serous carcinoma Hum Pathol 29 1998 613 619
11. S.A. King, A.A. Adas, and V.A. Livolsi Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma Cancer 75 1995 2700 2705
12. J.C. Irwin, L. de las Fuentes, B.A. Dsupin, and L.C. Giudice Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion Reg Peptides 48 1993 165 177
13. J.C. Irwin, L. de las Fuentes, and L.C. Giudice Growth factors and decidualization in vitro Ann New York Acad Sci 734 1994 7 18
14. H. Werner, and S. Maor The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action Trends Endocrinol Metab 17 2006 236 242
15. A.A. Samani, S. Yakar, D. LeRoith, and P. Brodt The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocrine Rev 28 2007 20 47
16. H. Werner The pathophysiological significance of IGF-I receptor overexpression: new insights Ped Endocrinol Rev 7 2009 2 5
17. R. Baserga, F. Peruzzi, and K. Reiss The IGF-1 receptor in cancer biology Int J Cancer 107 2003 873 877
18. H. Werner, and I. Bruchim The insulin-like growth factor-I receptor as an oncogene Arch Physiol Biochem 115 2009 58 71
19. A.S. McCampbell, R.R. Broaddus, D.S. Loose, and P.J. Davies Overexpression of the insulin-like growth factor-I receptor and activation of the AKT pathway in hyperplastic endometrium Clin Cancer Res 12 2006 6363 6378
20. I. Bruchim, Z. Attias, and H. Werner Targeting the IGF1 axis in cancer proliferation Exp Opinion Ther Targets 13 2009 1179 1192
21. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 2004 221 230
22. C. Garcia-Echeverria, M.A. Pearson, and A. Marti In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase Cancer Cell 5 2004 231 239
23. K. Scotlandi, and P. Picci Targeting insulin-like growth factor 1 receptor in sarcomas Curr Opinion Oncol 20 2008 419 427
24. J.S. Yuen, and V.M. Macaulay Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer Exp Opinion Ther Targets 12 2008 589 603
25. H. Werner, M. Woloschak, and M. Adamo Developmental regulation of the rat insulin-like growth factor I receptor gene Proc Natl Acad Sci USA 86 1989 7451 7455
26. S. Maor, D. Mayer, and R.I. Yarden Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1 J Endocrinol 191 2006 605 612
27. H. Schayek, H. Seti, and N.M. Greenberg Differential regulation of IGF1-R gene transcription by wild type and mutant androgen receptor in prostate cancer cells Mol Cell Endocrinol 323 2010 239 245
28. R. Sarfstein, A. Belfiore, and H. Werner Identification of insulin-like growth factor-I receptor gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells Cancers 2 2010 233 261
29. H. Schayek, K. Haugk, and S. Sun Tumor suppressor BRCA1 is expressed in prostate cancer and control IGF1-R gene transcription in an androgen receptor-dependent manner Clin Cancer Res 15 2009 1558 1565
30. H. Schayek, I. Bentov, and I. Rotem Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor gene Growth Hormone IGF Res 20 2010 68 72
31. H. Werner, E. Karnieli, F.J. Rauscher III, and D. LeRoith Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene Proc Natl Acad Sci USA 93 1996 8318 8323
32. C. Ohlsson, N. Kley, H. Werner, and D. LeRoith p53 regulates IGF-I receptor expression and IGF-I induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1 Endocrinology 139 1998 1101 1107
33. M.R. Hendrickson, T.A. Longacre, and R.L. Kempson Uterine papillary serous carcinoma revisited Gynecol Oncol 54 1994 261 263
34. A.D. Santin, S. Bellone, and M. Godken Overexpression of HER-2/Neu in uterine serous papillary cancer Clin Cancer Res 8 2002 1271 1279
35. D. Burtrum, Z. Zhu, and D. Lu A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 2003 8912 8921
36. H. Werner, M.A. Bach, and B. Stannard Structural and functional analysis of the insulin-like growth factor I receptor gene promoter Mol Endocrinol 6 1992 1545 1558
37. D. Beitner-Johnson, H. Werner, C.T. Roberts Jr, and D. LeRoith Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element Mol Endocrinol 9 1995 1147 1156
38. A.J. Levine, Z. Feng, and T.W. Mak Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways Genes Dev 20 2006 267 275
39. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
40. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
41. S.R. Datta, H. Dudek, and X. Tao Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
42. B.P. Zhou, Y. Liao, and W. Xia HER-2/neu induces p53 ubiquitination via Akt-mediated Mdm2 phosphorylation Nat Cell Biol 3 2001 973 982
43. A. Brunet, A. Bonni, and M.J. Zigmond Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868
44. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat Med 10 2004 789 799
45. V. Stambolic, D. MacPherson, and D. Sas Regulation of PTEN transcription by p53 Mol Cell 8 2001 317 325
46. J.D. Su, L.D. Mayo, D.B. Donner, and D.L. Durden PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment Cancer Res 63 2003 3585 3592
47. N.D. Lakin, and S.P. Jackson Regulation of p53 in response to DNA damage Oncogene 18 1999 7644 7655
48. L. Heron-Milhavet, and D. LeRoith Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage J Biol Chem 277 2002 15600 15606
49. L. Girnita, A. Girnita, and O. Larsson Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor-I receptor Proc Natl Acad Sci USA 100 2003 8247 8252
50. W.S. El-Deiry Regulation of p53 downstream genes Semin Cancer Biol 8 1998 345 357
51. M.F. McCarty Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy Integr Cancer Ther 3 2004 349 380
52. Z. Attias-Geva, I. Bentov, and D. Ludwig Insulin-like growth factor-I receptor targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-1 action in endometrial cancer cells Eur J Cancer 47 2010 1717 1726
53. R. Yerushalmi, K.A. Gelmon, and S. Leung Insulin-like growth factor receptor (IGF-IR) in breast subtypes Breast Cancer Res Treat 2011 [May 15, Epub ahead of print]